N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-N-(2,2,2-trifluoroethyl)benzenesulfonamide
AlkaPlorer ID: AK268173
Synonym: None
IUPAC Name: N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-N-(2,2,2-trifluoroethyl)benzenesulfonamide
Structure
SMILES: O=S(=O)(C1=CC=CC=C1)N(CC(F)(F)F)C1=CC=C(C(O)(C(F)(F)F)C(F)(F)F)C=C1
InChI: InChI=1S/C17H12F9NO3S/c18-14(19,20)10-27(31(29,30)13-4-2-1-3-5-13)12-8-6-11(7-9-12)15(28,16(21,22)23)17(24,25)26/h1-9,28H,10H2
InChIKey: SGIWFELWJPNFDH-UHFFFAOYSA-N
Reference
PubChem CID: 447912
CAS: 293754-55-9
SuperNatural Ⅲ: SN0344758
NPASS: NPC462908
COCONUT: CNP0373072
Source
| Species | Genus | Family | Order | Class | Phylum | Kingdom | Domain |
|---|---|---|---|---|---|---|---|
| Aspergillus puniceus | Aspergillus | Aspergillaceae | Eurotiales | Eurotiomycetes | Ascomycota | Fungi | Eukaryota |
Properties Information
Molecule Weight: 481.336
TPSA?: 57.61
MolLogP?: 4.756400000000003
Number of H-Donors: 1
Number of H-Acceptors: 3
RingCount: 2
Activities Information
| Organism | Target Name | Standard Type | Standard Value | Standard Units | doi |
|---|---|---|---|---|---|
| Canis lupus familiaris | Canis familiaris | AUC | 7301.0 | ng.hr.mL-1 | 10.1016/j.bmcl.2005.12.015 |
| Canis lupus familiaris | Canis familiaris | T1/2 | 5.8 | hr | 10.1016/j.bmcl.2005.12.015 |
| Cricetinae | Hamster | Activity | 40.0 | % | 10.1016/j.bmcl.2015.04.080 |
| Cricetinae | Hamster | Activity | 50.0 | % | 10.1016/j.bmcl.2015.01.047 |
| Cricetinae | Hamster | Activity | 52.0 | % | 10.1016/j.bmcl.2015.01.047 |
| Cricetinae | Hamster | Activity | 53.0 | % | 10.1016/j.bmcl.2015.01.047 |
| Cricetinae | Hamster | Activity | 59.0 | % | 10.1016/j.bmcl.2015.01.047 |
| Cricetinae | Hamster | Activity | 67.0 | % | 10.1016/j.bmcl.2015.01.047 |
| Cricetinae | Hamster | Activity | 75.0 | % | 10.1016/j.bmcl.2015.04.080 |
| Cricetinae | Hamster | Activity | 76.0 | % | 10.1016/j.bmcl.2015.04.080 |
| Cricetinae | Hamster | Activity | 123.0 | % | 10.1016/j.bmcl.2015.01.047 |
| Cricetinae | Hamster | Activity | 124.0 | % | 10.1016/j.bmcl.2015.04.080 |
| Cricetinae | Hamster | Activity | 127.0 | % | 10.1016/j.bmcl.2015.01.047 |
| Cricetinae | Hamster | Activity | 206.0 | % | 10.1016/j.bmcl.2015.01.047 |
| Cricetinae | Hamster | Activity | 243.0 | % | 10.1016/j.bmcl.2015.01.047 |
| Cricetinae | Hamster | Activity | 251.0 | % | 10.1016/j.bmcl.2015.04.080 |
| Cricetinae | Hamster | Activity | nan | None | 10.1016/j.bmcl.2015.01.047 |
| Cricetinae | Hamster | FC | 1.3 | None | 10.1016/j.bmcl.2015.04.080 |
| Cricetinae | Hamster | FC | 1.4 | None | 10.1016/j.bmcl.2015.04.080 |
| Cricetinae | Hamster | FC | 1.5 | None | 10.1016/j.bmcl.2015.04.080 |
| Cricetinae | Hamster | FC | 3.0 | None | 10.1016/j.bmcl.2015.01.047 |
| Cricetinae | Hamster | FC | 3.4 | None | 10.1016/j.bmcl.2015.04.080 |
| Homo sapiens | Aldehyde dehydrogenase 1A1 | Potency | 188.7 | nM | None |
| Homo sapiens | Alpha-synuclein | Potency | 35481.3 | nM | None |
| Homo sapiens | Androgen Receptor | Potency | 44668.4 | nM | None |
| Homo sapiens | Ataxin-2 | Potency | 22387.2 | nM | None |
| Homo sapiens | Bile acid receptor FXR | Activity | 2.05 | None | 10.1016/j.bmcl.2006.05.084 |
| Homo sapiens | Bile acid receptor FXR | EC50 | 1000.0 | nM | 10.1016/j.bmcl.2013.10.054 |
| Homo sapiens | Bile acid receptor FXR | EC50 | 1300.0 | nM | 10.1021/jm401901d |
| Homo sapiens | Bile acid receptor FXR | EC50 | 3400.0 | nM | 10.1016/j.bmcl.2016.02.031 |
| Homo sapiens | Bile acid receptor FXR | EC50 | 5000.0 | nM | None |
| Homo sapiens | Bile acid receptor FXR | FC | 77.0 | None | 10.1016/j.bmcl.2013.10.054 |
| Homo sapiens | Bile acid receptor FXR | IC50 | 5300.0 | nM | 10.1021/acs.jmedchem.9b00327 |
| Homo sapiens | Bile acid receptor FXR | Potency | 1778.3 | nM | None |
| Homo sapiens | Bile acid receptor FXR | Potency | 44668.4 | nM | None |
| Homo sapiens | Bromodomain-containing protein 4 | Delta TM | -2.49 | C | None |
| Homo sapiens | Bromodomain-containing protein 4 | Delta TM | -1.421 | C | None |
| Homo sapiens | Casein kinase I delta | Delta TM | 0.1 | C | None |
| Homo sapiens | Casein kinase I delta | Delta TM | 0.2167 | C | None |
| Homo sapiens | Cyclin-dependent kinase 2 | Delta TM | -1.358 | C | None |
| Homo sapiens | Cyclin-dependent kinase 2 | Delta TM | -0.3 | C | None |
| Homo sapiens | Dihydroorotate dehydrogenase | IC50 | nan | None | 10.1021/acs.jmedchem.1c01746 |
| Homo sapiens | DNA polymerase iota | Potency | 79432.8 | nM | None |
| Homo sapiens | DNA polymerase kappa | Potency | 35481.3 | nM | None |
| Homo sapiens | Estrogen receptor alpha | Potency | 44668.4 | nM | None |
| Homo sapiens | Fibroblast | Control DMSO Fragmented Nuclei % | 10.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Control DMSO Fragmented Nuclei % | 11.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Control DMSO Fragmented Nuclei % | 12.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Control DMSO Fragmented Nuclei % | 15.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Control DMSO Fragmented Nuclei % | 18.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Control DMSO Healthy Nuclei (%) | 60.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Control DMSO Healthy Nuclei (%) | 62.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Control DMSO Healthy Nuclei (%) | 66.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Control DMSO Healthy Nuclei (%) | 67.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Control DMSO Healthy Nuclei (%) | 68.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Control DMSO Healthy Nuclei (%) | 69.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Control DMSO Healthy Nuclei (%) | 70.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Control DMSO Healthy Nuclei (%) | 72.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Control DMSO Membrane Permeable-Phenotype Cells (%) | 0.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Control DMSO Membrane Permeable-Phenotype Cells (%) | 1.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Control DMSO Membrane Permeable-Phenotype Cells (%) | 4.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Control DMSO Membrane Permeable-Phenotype Cells (%) | 5.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Control DMSO Mitochondria Different-Phenotype Cells (%) | 0.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Control DMSO Mitochondria Different-Phenotype Cells (%) | 1.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Control DMSO Mitochondria Different-Phenotype Cells (%) | 15.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Control DMSO Mitotic Cells (%) | 31.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Control DMSO Mitotic Cells (%) | 37.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Control DMSO Mitotic Cells (%) | 49.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Control DMSO Mitotic Cells (%) | 56.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Control DMSO Mitotic Cells (%) | 59.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Control DMSO Mitotic Cells (%) | 61.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Control DMSO Mitotic Cells (%) | 62.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Control DMSO Pyknosed Nuclei (%) | 15.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Control DMSO Pyknosed Nuclei (%) | 16.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Control DMSO Pyknosed Nuclei (%) | 20.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Control DMSO Pyknosed Nuclei (%) | 21.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Control DMSO Pyknosed Nuclei (%) | 22.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Control DMSO Total Cells | 127.0 | None | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Control DMSO Total Cells | 131.0 | None | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Control DMSO Total Cells | 198.0 | None | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Control DMSO Total Cells | 199.0 | None | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Control DMSO Total Cells | 205.0 | None | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Control DMSO Total Cells | 208.0 | None | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Control DMSO Total Cells | 212.0 | None | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Control DMSO Total Cells | 216.0 | None | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Control DMSO Tubulin Phenotype Different Cells (%) | 4.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Control DMSO Tubulin Phenotype Different Cells (%) | 5.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Control DMSO Tubulin Phenotype Different Cells (%) | 7.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Control DMSO Tubulin Phenotype Different Cells (%) | 8.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Control DMSO Tubulin Phenotype Different Cells (%) | 9.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Control DMSO Tubulin Phenotype Different Cells (%) | 10.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Control DMSO Tubulin Phenotype Different Cells (%) | 11.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Growth Rate | -0.32 | None | 10.6019/CHEMBL5058564 |
| Homo sapiens | Fibroblast | Growth Rate | -0.3 | None | 10.6019/CHEMBL5058564 |
| Homo sapiens | Fibroblast | Growth Rate | -0.09 | None | 10.6019/CHEMBL5058564 |
| Homo sapiens | Fibroblast | Growth Rate | 0.0 | None | 10.6019/CHEMBL4689842 |
| Homo sapiens | Fibroblast | Growth Rate | 0.05 | None | 10.6019/CHEMBL5058564 |
| Homo sapiens | Fibroblast | Growth Rate | 0.22 | None | 10.6019/CHEMBL5058564 |
| Homo sapiens | Fibroblast | Growth Rate | 0.72 | None | 10.6019/CHEMBL5058564 |
| Homo sapiens | Fibroblast | Population Apoptotic (%) | 27.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Population Apoptotic (%) | 28.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Population Apoptotic (%) | 30.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Population Apoptotic (%) | 33.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Population Apoptotic (%) | 37.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Population Apoptotic (%) | 43.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Population Apoptotic (%) | 45.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Population Apoptotic (%) | 50.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Population Apoptotic (%) | 52.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Population Apoptotic (%) | 63.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Population Apoptotic (%) | 66.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Population Apoptotic (%) | 69.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Population Apoptotic (%) | 71.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Population Apoptotic (%) | 75.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Population Apoptotic (%) | 78.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Population Fragmented Nuclei (%) | 10.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Population Fragmented Nuclei (%) | 11.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Population Fragmented Nuclei (%) | 12.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Population Fragmented Nuclei (%) | 13.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Population Fragmented Nuclei (%) | 14.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Population Fragmented Nuclei (%) | 15.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Population Fragmented Nuclei (%) | 16.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Population Fragmented Nuclei (%) | 18.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Population Fragmented Nuclei (%) | 19.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Population Fragmented Nuclei (%) | 25.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Population Fragmented Nuclei (%) | 26.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Population Fragmented Nuclei (%) | 30.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Population Healthy Nuclei (%) | 46.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Population Healthy Nuclei (%) | 47.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Population Healthy Nuclei (%) | 50.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Population Healthy Nuclei (%) | 54.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Population Healthy Nuclei (%) | 57.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Population Healthy Nuclei (%) | 58.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Population Healthy Nuclei (%) | 60.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Population Healthy Nuclei (%) | 66.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Population Healthy Nuclei (%) | 67.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Population Healthy Nuclei (%) | 68.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Population Hoechst High Intensity Objects (%) | 0.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Population Hoechst High Intensity Objects (%) | 1.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Population Membrane Permeable-Phenotype (%) | 0.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Population Membrane Permeable-Phenotype (%) | 1.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Population Membrane Permeable-Phenotype (%) | 6.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Population Membrane Permeable-Phenotype (%) | 7.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Population Membrane Permeable-Phenotype (%) | 8.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Population Membrane Permeable-Phenotype (%) | 10.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Population Membrane Permeable-Phenotype (%) | 14.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Population Membrane Permeable-Phenotype (%) | 15.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Population Membrane Permeable-Phenotype (%) | 16.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Population Membrane Permeable-Phenotype (%) | 17.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Population Membrane Permeable-Phenotype (%) | 26.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Population Mitochondria Different-Phenotype (%) | 0.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Population Mitochondria Different-Phenotype (%) | 1.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Population Mitochondria Different-Phenotype (%) | 2.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Population Mitochondria Different-Phenotype (%) | 4.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Population Mitochondria Different-Phenotype (%) | 5.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Population Mitochondria Different-Phenotype (%) | 7.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Population Mitochondria Different-Phenotype (%) | 10.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Population Mitochondria Different-Phenotype (%) | 14.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Population Mitochondria Different-Phenotype (%) | 22.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Population Mitochondria Different-Phenotype (%) | 25.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Population Mitotic Cells (%) | 21.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Population Mitotic Cells (%) | 24.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Population Mitotic Cells (%) | 28.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Population Mitotic Cells (%) | 30.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Population Mitotic Cells (%) | 33.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Population Mitotic Cells (%) | 36.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Population Mitotic Cells (%) | 47.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Population Mitotic Cells (%) | 50.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Population Mitotic Cells (%) | 54.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Population Mitotic Cells (%) | 56.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Population Mitotic Cells (%) | 62.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Population Mitotic Cells (%) | 66.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Population Mitotic Cells (%) | 69.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Population Mitotic Cells (%) | 71.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Population Mitotic Cells (%) | 72.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Population Normal (%) | 98.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Population Normal (%) | 99.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Population Normal (%) | 100.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Population Pyknosed Nuclei (%) | 14.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Population Pyknosed Nuclei (%) | 19.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Population Pyknosed Nuclei (%) | 20.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Population Pyknosed Nuclei (%) | 21.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Population Pyknosed Nuclei (%) | 24.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Population Pyknosed Nuclei (%) | 25.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Population Pyknosed Nuclei (%) | 27.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Population Pyknosed Nuclei (%) | 28.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Population Pyknosed Nuclei (%) | 29.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Population Pyknosed Nuclei (%) | 31.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Population Pyknosed Nuclei (%) | 35.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Population Tubulin-Different-Phenotype (%) | 1.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Population Tubulin-Different-Phenotype (%) | 12.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Population Tubulin-Different-Phenotype (%) | 21.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Population Tubulin-Different-Phenotype (%) | 24.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Population Tubulin-Different-Phenotype (%) | 28.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Population Tubulin-Different-Phenotype (%) | 32.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Population Tubulin-Different-Phenotype (%) | 34.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Population Tubulin-Different-Phenotype (%) | 40.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Population Tubulin-Different-Phenotype (%) | 56.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Population Tubulin-Different-Phenotype (%) | 65.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Population Tubulin-Different-Phenotype (%) | 69.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Population Tubulin-Different-Phenotype (%) | 80.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Total Cell Count | 92.0 | None | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Total Cell Count | 98.0 | None | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Total Cell Count | 101.0 | None | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Total Cell Count | 108.0 | None | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Total Cell Count | 128.0 | None | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Total Cell Count | 132.0 | None | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Total Cell Count | 134.0 | None | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Total Cell Count | 135.0 | None | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Total Cell Count | 143.0 | None | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Total Cell Count | 145.0 | None | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Total Cell Count | 151.0 | None | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Total Cell Count | 175.0 | None | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Total Cell Count | 204.0 | None | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast | Total Cell Count | 214.0 | None | 10.6019/CHEMBL5303300 |
| Homo sapiens | Fibroblast growth factor receptor 3 | Delta TM | -0.1921 | C | None |
| Homo sapiens | Fibroblast growth factor receptor 3 | Delta TM | -0.13 | C | None |
| Homo sapiens | Gamma-secretase | EC50 | 3600.0 | nM | 10.1016/j.bmcl.2007.07.044 |
| Homo sapiens | Gamma-secretase | IC50 | 4500.0 | nM | 10.1016/j.bmcl.2007.07.044 |
| Homo sapiens | Gamma-secretase | IC50 | 40000.0 | nM | 10.1016/j.bmcl.2007.07.044 |
| Homo sapiens | Glucagon-like peptide 1 receptor | Potency | 11220.2 | nM | None |
| Homo sapiens | Glucocorticoid receptor | Potency | 39810.7 | nM | None |
| Homo sapiens | Glycogen synthase kinase-3 beta | Delta TM | -0.4 | C | None |
| Homo sapiens | Glycogen synthase kinase-3 beta | Delta TM | 0.4668 | C | None |
| Homo sapiens | Glycogen synthase kinase-3 beta | IC50 | nan | nM | 10.1021/jm050532w |
| Homo sapiens | HEK-293T | Control DMSO Fragmented Nuclei % | 3.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Control DMSO Fragmented Nuclei % | 6.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Control DMSO Fragmented Nuclei % | 12.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Control DMSO Fragmented Nuclei % | 14.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Control DMSO Healthy Nuclei (%) | 69.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Control DMSO Healthy Nuclei (%) | 70.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Control DMSO Healthy Nuclei (%) | 82.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Control DMSO Healthy Nuclei (%) | 84.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Control DMSO Healthy Nuclei (%) | 85.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Control DMSO Healthy Nuclei (%) | 86.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Control DMSO Membrane Permeable-Phenotype Cells (%) | 0.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Control DMSO Membrane Permeable-Phenotype Cells (%) | 1.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Control DMSO Membrane Permeable-Phenotype Cells (%) | 2.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Control DMSO Membrane Permeable-Phenotype Cells (%) | 3.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Control DMSO Membrane Permeable-Phenotype Cells (%) | 4.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Control DMSO Mitochondria Different-Phenotype Cells (%) | 0.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Control DMSO Mitochondria Different-Phenotype Cells (%) | 4.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Control DMSO Mitochondria Different-Phenotype Cells (%) | 5.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Control DMSO Mitochondria Different-Phenotype Cells (%) | 6.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Control DMSO Mitochondria Different-Phenotype Cells (%) | 7.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Control DMSO Mitochondria Different-Phenotype Cells (%) | 13.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Control DMSO Mitochondria Different-Phenotype Cells (%) | 14.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Control DMSO Mitotic Cells (%) | 49.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Control DMSO Mitotic Cells (%) | 54.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Control DMSO Mitotic Cells (%) | 57.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Control DMSO Mitotic Cells (%) | 60.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Control DMSO Mitotic Cells (%) | 62.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Control DMSO Mitotic Cells (%) | 81.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Control DMSO Mitotic Cells (%) | 85.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Control DMSO Pyknosed Nuclei (%) | 3.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Control DMSO Pyknosed Nuclei (%) | 7.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Control DMSO Pyknosed Nuclei (%) | 8.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Control DMSO Pyknosed Nuclei (%) | 11.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Control DMSO Pyknosed Nuclei (%) | 26.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Control DMSO Total Cells | 364.0 | None | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Control DMSO Total Cells | 370.0 | None | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Control DMSO Total Cells | 680.0 | None | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Control DMSO Total Cells | 681.0 | None | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Control DMSO Total Cells | 1046.0 | None | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Control DMSO Total Cells | 1069.0 | None | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Control DMSO Total Cells | 2439.0 | None | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Control DMSO Total Cells | 2812.0 | None | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Control DMSO Tubulin Phenotype Different Cells (%) | 10.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Control DMSO Tubulin Phenotype Different Cells (%) | 11.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Control DMSO Tubulin Phenotype Different Cells (%) | 12.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Control DMSO Tubulin Phenotype Different Cells (%) | 13.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Control DMSO Tubulin Phenotype Different Cells (%) | 25.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Control DMSO Tubulin Phenotype Different Cells (%) | 27.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Control DMSO Tubulin Phenotype Different Cells (%) | 47.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Control DMSO Tubulin Phenotype Different Cells (%) | 48.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Growth Rate | 0.0 | None | 10.6019/CHEMBL4689842 |
| Homo sapiens | HEK-293T | Growth Rate | 0.24 | None | 10.6019/CHEMBL5058564 |
| Homo sapiens | HEK-293T | Growth Rate | 0.37 | None | 10.6019/CHEMBL5058564 |
| Homo sapiens | HEK-293T | Growth Rate | 0.42 | None | 10.6019/CHEMBL5058564 |
| Homo sapiens | HEK-293T | Growth Rate | 0.53 | None | 10.6019/CHEMBL5058564 |
| Homo sapiens | HEK-293T | Growth Rate | 0.56 | None | 10.6019/CHEMBL5058564 |
| Homo sapiens | HEK-293T | Growth Rate | 0.75 | None | 10.6019/CHEMBL5058564 |
| Homo sapiens | HEK-293T | Growth Rate | 0.77 | None | 10.6019/CHEMBL5058564 |
| Homo sapiens | HEK-293T | Growth Rate | 0.85 | None | 10.6019/CHEMBL5058564 |
| Homo sapiens | HEK-293T | Growth Rate | 1.0 | None | 10.6019/CHEMBL4689842 |
| Homo sapiens | HEK-293T | Population Apoptotic (%) | 9.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Apoptotic (%) | 28.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Apoptotic (%) | 31.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Apoptotic (%) | 36.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Apoptotic (%) | 39.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Apoptotic (%) | 40.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Apoptotic (%) | 42.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Apoptotic (%) | 44.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Apoptotic (%) | 48.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Apoptotic (%) | 54.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Apoptotic (%) | 56.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Apoptotic (%) | 57.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Apoptotic (%) | 67.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Apoptotic (%) | 68.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Apoptotic (%) | 74.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Fragmented Nuclei (%) | 2.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Fragmented Nuclei (%) | 3.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Fragmented Nuclei (%) | 4.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Fragmented Nuclei (%) | 5.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Fragmented Nuclei (%) | 7.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Fragmented Nuclei (%) | 8.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Fragmented Nuclei (%) | 14.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Fragmented Nuclei (%) | 15.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Healthy Nuclei (%) | 66.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Healthy Nuclei (%) | 68.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Healthy Nuclei (%) | 72.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Healthy Nuclei (%) | 75.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Healthy Nuclei (%) | 78.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Healthy Nuclei (%) | 79.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Healthy Nuclei (%) | 80.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Healthy Nuclei (%) | 81.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Healthy Nuclei (%) | 82.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Healthy Nuclei (%) | 83.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Healthy Nuclei (%) | 84.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Healthy Nuclei (%) | 85.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Healthy Nuclei (%) | 87.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Hoechst High Intensity Objects (%) | 3.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Hoechst High Intensity Objects (%) | 4.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Hoechst High Intensity Objects (%) | 5.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Hoechst High Intensity Objects (%) | 7.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Hoechst High Intensity Objects (%) | 8.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Hoechst High Intensity Objects (%) | 9.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Hoechst High Intensity Objects (%) | 10.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Hoechst High Intensity Objects (%) | 14.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Hoechst High Intensity Objects (%) | 15.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Hoechst High Intensity Objects (%) | 18.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Hoechst High Intensity Objects (%) | 24.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Membrane Permeable-Phenotype (%) | 0.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Membrane Permeable-Phenotype (%) | 1.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Membrane Permeable-Phenotype (%) | 2.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Membrane Permeable-Phenotype (%) | 3.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Membrane Permeable-Phenotype (%) | 4.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Membrane Permeable-Phenotype (%) | 6.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Mitochondria Different-Phenotype (%) | 0.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Mitochondria Different-Phenotype (%) | 2.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Mitochondria Different-Phenotype (%) | 5.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Mitochondria Different-Phenotype (%) | 7.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Mitochondria Different-Phenotype (%) | 8.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Mitochondria Different-Phenotype (%) | 9.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Mitochondria Different-Phenotype (%) | 15.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Mitochondria Different-Phenotype (%) | 22.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Mitochondria Different-Phenotype (%) | 42.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Mitochondria Different-Phenotype (%) | 49.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Mitochondria Different-Phenotype (%) | 53.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Mitochondria Different-Phenotype (%) | 58.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Mitochondria Different-Phenotype (%) | 59.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Mitochondria Different-Phenotype (%) | 66.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Mitotic Cells (%) | 25.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Mitotic Cells (%) | 31.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Mitotic Cells (%) | 32.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Mitotic Cells (%) | 42.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Mitotic Cells (%) | 43.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Mitotic Cells (%) | 45.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Mitotic Cells (%) | 51.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Mitotic Cells (%) | 55.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Mitotic Cells (%) | 57.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Mitotic Cells (%) | 59.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Mitotic Cells (%) | 60.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Mitotic Cells (%) | 63.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Mitotic Cells (%) | 68.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Mitotic Cells (%) | 71.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Mitotic Cells (%) | 90.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Normal (%) | 75.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Normal (%) | 81.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Normal (%) | 84.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Normal (%) | 85.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Normal (%) | 89.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Normal (%) | 90.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Normal (%) | 91.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Normal (%) | 92.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Normal (%) | 94.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Normal (%) | 95.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Normal (%) | 96.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Pyknosed Nuclei (%) | 3.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Pyknosed Nuclei (%) | 8.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Pyknosed Nuclei (%) | 10.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Pyknosed Nuclei (%) | 11.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Pyknosed Nuclei (%) | 12.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Pyknosed Nuclei (%) | 13.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Pyknosed Nuclei (%) | 14.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Pyknosed Nuclei (%) | 19.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Pyknosed Nuclei (%) | 24.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Pyknosed Nuclei (%) | 27.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Pyknosed Nuclei (%) | 28.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Tubulin-Different-Phenotype (%) | 10.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Tubulin-Different-Phenotype (%) | 14.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Tubulin-Different-Phenotype (%) | 16.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Tubulin-Different-Phenotype (%) | 19.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Tubulin-Different-Phenotype (%) | 22.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Tubulin-Different-Phenotype (%) | 36.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Tubulin-Different-Phenotype (%) | 38.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Tubulin-Different-Phenotype (%) | 56.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Tubulin-Different-Phenotype (%) | 81.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Tubulin-Different-Phenotype (%) | 82.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Tubulin-Different-Phenotype (%) | 86.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Tubulin-Different-Phenotype (%) | 87.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Population Tubulin-Different-Phenotype (%) | 94.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Total Cell Count | 264.0 | None | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Total Cell Count | 279.0 | None | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Total Cell Count | 296.0 | None | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Total Cell Count | 318.0 | None | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Total Cell Count | 373.0 | None | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Total Cell Count | 376.0 | None | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Total Cell Count | 385.0 | None | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Total Cell Count | 411.0 | None | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Total Cell Count | 426.0 | None | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Total Cell Count | 429.0 | None | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Total Cell Count | 522.0 | None | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Total Cell Count | 697.0 | None | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Total Cell Count | 740.0 | None | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Total Cell Count | 1214.0 | None | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Total Cell Count | 1428.0 | None | 10.6019/CHEMBL5303300 |
| Homo sapiens | HEK-293T | Total Cell Count | 2956.0 | None | 10.6019/CHEMBL5303300 |
| Homo sapiens | Hepatocyte | Activity | nan | None | 10.1021/jm070453f |
| Homo sapiens | HepG2 | Activity | 100.0 | % | 10.1016/j.bmcl.2007.11.013 |
| Homo sapiens | HepG2 | Activity | 100.0 | % | 10.1016/j.bmcl.2010.03.031 |
| Homo sapiens | HepG2 | Activity | 175.0 | % | 10.1021/jm301913k |
| Homo sapiens | HepG2 | Activity | nan | None | 10.1016/j.bmcl.2012.04.071 |
| Homo sapiens | HepG2 | Activity | nan | None | 10.1021/jm301913k |
| Homo sapiens | HepG2 | EC50 | 61.0 | nM | 10.1021/jm800799q |
| Homo sapiens | HepG2 | EC50 | 67.0 | nM | 10.1016/j.bmcl.2007.11.013 |
| Homo sapiens | HepG2 | EC50 | 104.0 | nM | 10.1016/j.bmcl.2009.11.099 |
| Homo sapiens | HepG2 | EC50 | 107.0 | nM | 10.1016/j.bmcl.2010.03.031 |
| Homo sapiens | HepG2 | EC50 | 137.0 | nM | 10.1016/j.bmcl.2009.11.062 |
| Homo sapiens | HepG2 | EC50 | 137.0 | nM | 10.1016/j.bmcl.2009.11.098 |
| Homo sapiens | HepG2 | EC50 | 137.0 | nM | 10.1021/jm800799q |
| Homo sapiens | HepG2 | EC50 | 140.0 | nM | 10.1021/jm100034x |
| Homo sapiens | HepG2 | Efficacy | 100.0 | % | 10.1016/j.bmcl.2009.11.098 |
| Homo sapiens | HepG2 | Efficacy | 100.0 | % | 10.1016/j.bmcl.2009.11.099 |
| Homo sapiens | HepG2 | Efficacy | 100.0 | % | 10.1021/jm800799q |
| Homo sapiens | HepG2 | IC50 relative | 13400.0 | nM | 10.6019/EOS300108 |
| Homo sapiens | HepG2 | Potency | 22387.2 | nM | None |
| Homo sapiens | HepG2 | Potency | 35481.3 | nM | None |
| Homo sapiens | HepG2 | Ratio | 3.6 | None | 10.1016/j.bmcl.2007.03.076 |
| Homo sapiens | HepG2 | Ratio | 3.6 | None | 10.1016/j.bmcl.2007.06.017 |
| Homo sapiens | HepG2 | Ratio | 6.7 | None | 10.1016/j.bmcl.2007.06.017 |
| Homo sapiens | Histone deacetylase 6 | Inhibition | 2.06 | % | 10.6019/CHEMBL4808148 |
| Homo sapiens | Histone deacetylase 6 | Inhibition | 3.04 | % | 10.6019/CHEMBL4808148 |
| Homo sapiens | Huh-7 | Activity | 1.0 | None | 10.1021/jm800612u |
| Homo sapiens | Huh-7 | Activity | 100.0 | % | 10.1016/j.bmcl.2010.03.031 |
| Homo sapiens | Huh-7 | EC50 | 36.0 | nM | 10.1016/j.bmcl.2010.03.031 |
| Homo sapiens | Huh-7 | EC50 | 67.0 | nM | 10.1016/j.bmc.2009.04.012 |
| Homo sapiens | Isocitrate dehydrogenase [NADP] cytoplasmic | Potency | 23109.3 | nM | None |
| Homo sapiens | Liver microsomes | T1/2 | 0.5 | hr | 10.1016/j.bmcl.2009.10.132 |
| Homo sapiens | Liver microsomes | T1/2 | 0.5 | hr | 10.1016/j.bmcl.2009.11.098 |
| Homo sapiens | Liver microsomes | T1/2 | 0.5 | hr | 10.1016/j.bmcl.2010.03.031 |
| Homo sapiens | Liver X receptor | Activity | -11.0 | % | 10.1016/j.bmcl.2013.05.030 |
| Homo sapiens | Liver X receptor | Activity | 99.0 | % | 10.1016/j.bmcl.2007.11.013 |
| Homo sapiens | Liver X receptor | Activity | nan | None | 10.1016/j.bmc.2013.10.024 |
| Homo sapiens | Liver X receptor | Activity | nan | None | 10.1016/j.bmcl.2012.04.071 |
| Homo sapiens | Liver X receptor | Activity | nan | None | 10.1016/j.ejmech.2014.01.003 |
| Homo sapiens | Liver X receptor | EC50 | 17.0 | nM | 10.1016/j.bmcl.2014.11.029 |
| Homo sapiens | Liver X receptor | EC50 | 137.0 | nM | 10.1016/j.bmcl.2007.11.013 |
| Homo sapiens | Liver X receptor | EC50 | 170.0 | nM | 10.1016/j.bmcl.2009.10.132 |
| Homo sapiens | Liver X receptor | Efficacy | 89.0 | % | 10.1016/j.bmcl.2014.11.029 |
| Homo sapiens | Liver X receptor | Efficacy | 100.0 | % | 10.1016/j.bmcl.2009.10.132 |
| Homo sapiens | Liver X receptor | FC | 0.6 | None | 10.1021/jm3002394 |
| Homo sapiens | Liver X receptor | FC | 2.6 | None | 10.1016/j.bmcl.2013.05.030 |
| Homo sapiens | Liver X receptor | FC | 2.621 | None | 10.1016/j.bmcl.2018.12.025 |
| Homo sapiens | Liver X receptor | FC | 3.2 | None | 10.1016/j.bmcl.2013.05.030 |
| Homo sapiens | Liver X receptor | FC | 4.82 | None | 10.1021/acs.jmedchem.5b02029 |
| Homo sapiens | Liver X receptor | FC | 5.38 | None | 10.1021/acs.jmedchem.5b02029 |
| Homo sapiens | Liver X receptor | FC | 8.6 | None | 10.1016/j.bmcl.2013.05.030 |
| Homo sapiens | Liver X receptor | FC | 8.95 | None | 10.1016/j.bmcl.2018.12.025 |
| Homo sapiens | Liver X receptor | FC | 18.1 | None | 10.1016/j.bmcl.2013.05.030 |
| Homo sapiens | Liver X receptor | IC50 | 10000.0 | nM | 10.1021/jm3002394 |
| Homo sapiens | Liver X receptor | IC50 | 26000.0 | nM | 10.1021/acsmedchemlett.5b00170 |
| Homo sapiens | Liver X receptor | Inhibition | 49.0 | % | 10.1021/jm3002394 |
| Homo sapiens | Liver X receptor (LXR alpha AND LXR beta) | Ratio IC50 | 1.0 | None | 10.1016/j.bmcl.2009.11.062 |
| Homo sapiens | Liver X receptor (LXR alpha AND LXR beta) | Ratio IC50 | 1.0 | None | 10.1016/j.bmcl.2009.11.099 |
| Homo sapiens | Liver X receptor (LXR alpha AND LXR beta) | Ratio IC50 | 1.4 | None | 10.1016/j.bmc.2009.04.012 |
| Homo sapiens | Liver X receptor (LXR alpha AND LXR beta) | Ratio IC50 | 1.4 | None | 10.1016/j.bmcl.2007.11.013 |
| Homo sapiens | LXR-alpha | Activity | 96.0 | % | 10.1016/j.bmcl.2013.05.030 |
| Homo sapiens | LXR-alpha | Activity | 100.0 | % | 10.1016/j.bmcl.2007.11.013 |
| Homo sapiens | LXR-alpha | Activity | nan | None | 10.1016/j.bmcl.2012.04.071 |
| Homo sapiens | LXR-alpha | Activity | nan | None | 10.1016/j.bmcl.2017.12.024 |
| Homo sapiens | LXR-alpha | Activity | nan | None | 10.1021/jm100034x |
| Homo sapiens | LXR-alpha | Activity | nan | None | 10.1021/jm3002394 |
| Homo sapiens | LXR-alpha | EC50 | 3.2 | nM | 10.1021/jm101063h |
| Homo sapiens | LXR-alpha | EC50 | 6.0 | nM | 10.1016/j.bmcl.2017.12.024 |
| Homo sapiens | LXR-alpha | EC50 | 10.0 | nM | 10.1016/j.bmcl.2005.12.015 |
| Homo sapiens | LXR-alpha | EC50 | 10.0 | nM | 10.1016/j.bmcl.2009.02.039 |
| Homo sapiens | LXR-alpha | EC50 | 20.0 | nM | 10.1021/acs.jmedchem.6b00176 |
| Homo sapiens | LXR-alpha | EC50 | 28.0 | nM | 10.1016/j.bmcl.2014.11.029 |
| Homo sapiens | LXR-alpha | EC50 | 30.0 | nM | 10.1016/j.bmcl.2015.07.047 |
| Homo sapiens | LXR-alpha | EC50 | 40.0 | nM | 10.1016/j.bmcl.2007.03.076 |
| Homo sapiens | LXR-alpha | EC50 | 40.0 | nM | 10.1016/j.bmcl.2007.06.017 |
| Homo sapiens | LXR-alpha | EC50 | 50.0 | nM | 10.1021/acs.jmedchem.8b01848 |
| Homo sapiens | LXR-alpha | EC50 | 55.0 | nM | 10.1021/jm050532w |
| Homo sapiens | LXR-alpha | EC50 | 60.0 | nM | 10.1021/jm0255116 |
| Homo sapiens | LXR-alpha | EC50 | 63.1 | nM | 10.1021/jm901797p |
| Homo sapiens | LXR-alpha | EC50 | 85.0 | nM | 10.1016/j.bmcl.2009.02.039 |
| Homo sapiens | LXR-alpha | EC50 | 85.0 | nM | 10.1021/jm0255116 |
| Homo sapiens | LXR-alpha | EC50 | 91.1 | nM | 10.1016/j.bmcl.2013.05.030 |
| Homo sapiens | LXR-alpha | EC50 | 120.0 | nM | 10.1039/C9MD00264B |
| Homo sapiens | LXR-alpha | EC50 | 135.0 | nM | 10.1016/j.bmc.2009.04.012 |
| Homo sapiens | LXR-alpha | EC50 | 135.0 | nM | 10.1016/j.bmcl.2007.11.013 |
| Homo sapiens | LXR-alpha | EC50 | 140.0 | nM | 10.1016/j.bmcl.2009.11.062 |
| Homo sapiens | LXR-alpha | EC50 | 140.0 | nM | 10.1021/jm800799q |
| Homo sapiens | LXR-alpha | EC50 | 170.0 | nM | 10.1016/j.bmcl.2009.11.098 |
| Homo sapiens | LXR-alpha | EC50 | 190.0 | nM | 10.1007/s00044-012-0359-5 |
| Homo sapiens | LXR-alpha | EC50 | 210.0 | nM | 10.1021/acsmedchemlett.5b00170 |
| Homo sapiens | LXR-alpha | EC50 | 250.0 | nM | 10.1016/j.bmcl.2006.06.081 |
| Homo sapiens | LXR-alpha | EC50 | 250.0 | nM | 10.1039/C3MD00005B |
| Homo sapiens | LXR-alpha | EC50 | 260.0 | nM | 10.1016/j.bmc.2022.116792 |
| Homo sapiens | LXR-alpha | EC50 | 290.0 | nM | 10.1016/j.bmc.2014.03.007 |
| Homo sapiens | LXR-alpha | EC50 | 340.0 | nM | 10.1021/jm3002394 |
| Homo sapiens | LXR-alpha | EC50 | 359.0 | nM | 10.1016/j.bmcl.2017.12.006 |
| Homo sapiens | LXR-alpha | EC50 | 370.0 | nM | 10.1021/jm401901d |
| Homo sapiens | LXR-alpha | EC50 | 373.0 | nM | 10.1016/j.bmcl.2013.10.054 |
| Homo sapiens | LXR-alpha | EC50 | 400.0 | nM | 10.1016/j.bmcl.2016.02.031 |
| Homo sapiens | LXR-alpha | EC50 | 490.0 | nM | 10.1016/j.bmc.2016.05.048 |
| Homo sapiens | LXR-alpha | EC50 | 490.0 | nM | 10.1016/j.bmcl.2015.01.047 |
| Homo sapiens | LXR-alpha | EC50 | 500.0 | nM | 10.1016/j.bmcl.2015.04.080 |
| Homo sapiens | LXR-alpha | EC50 | 530.0 | nM | 10.1021/acs.jnatprod.9b00055 |
| Homo sapiens | LXR-alpha | EC50 | 940.0 | nM | 10.1016/j.bmcl.2017.01.066 |
| Homo sapiens | LXR-alpha | EC50 | 1430.0 | nM | 10.1016/j.bmcl.2012.04.071 |
| Homo sapiens | LXR-alpha | Efficacy | 100.0 | % | 10.1016/j.bmcl.2014.11.029 |
| Homo sapiens | LXR-alpha | Efficacy | 100.0 | % | 10.1021/jm800799q |
| Homo sapiens | LXR-alpha | Efficacy | 124.0 | % | 10.1021/jm3002394 |
| Homo sapiens | LXR-alpha | Emax | 100.0 | % | 10.1016/j.bmc.2016.05.048 |
| Homo sapiens | LXR-alpha | Emax | 100.0 | % | 10.1016/j.bmcl.2015.01.047 |
| Homo sapiens | LXR-alpha | Emax | 100.0 | % | 10.1016/j.bmcl.2015.04.080 |
| Homo sapiens | LXR-alpha | Emax | 100.0 | % | 10.1021/acs.jmedchem.6b00176 |
| Homo sapiens | LXR-alpha | FC | 0.66 | None | 10.1007/s00044-012-0359-5 |
| Homo sapiens | LXR-alpha | FC | 2.2 | None | 10.1007/s00044-012-0359-5 |
| Homo sapiens | LXR-alpha | FC | 2.6 | None | 10.1007/s00044-012-0359-5 |
| Homo sapiens | LXR-alpha | FC | 2.61 | None | 10.1007/s00044-012-0359-5 |
| Homo sapiens | LXR-alpha | FC | 19.3 | None | 10.1021/acs.jnatprod.9b00055 |
| Homo sapiens | LXR-alpha | FC | 643.0 | None | 10.1016/j.bmcl.2013.10.054 |
| Homo sapiens | LXR-alpha | IC50 | 9.0 | nM | 10.1016/j.bmcl.2009.10.132 |
| Homo sapiens | LXR-alpha | IC50 | 9.0 | nM | 10.1016/j.bmcl.2009.11.098 |
| Homo sapiens | LXR-alpha | IC50 | 9.0 | nM | 10.1016/j.bmcl.2009.11.099 |
| Homo sapiens | LXR-alpha | IC50 | 10.0 | nM | 10.1021/jm0609566 |
| Homo sapiens | LXR-alpha | IC50 | 13.0 | nM | 10.1016/j.bmc.2009.10.001 |
| Homo sapiens | LXR-alpha | IC50 | 13.0 | nM | 10.1016/j.bmcl.2007.11.013 |
| Homo sapiens | LXR-alpha | IC50 | 13.0 | nM | 10.1016/j.bmcl.2009.11.062 |
| Homo sapiens | LXR-alpha | IC50 | 13.0 | nM | 10.1016/j.bmcl.2010.03.031 |
| Homo sapiens | LXR-alpha | IC50 | 13.0 | nM | 10.1021/jm100034x |
| Homo sapiens | LXR-alpha | IC50 | 13.0 | nM | 10.1021/jm800799q |
| Homo sapiens | LXR-alpha | IC50 | 30.0 | nM | 10.1016/j.bmcl.2006.06.081 |
| Homo sapiens | LXR-alpha | IC50 | 50.0 | nM | 10.1021/acs.jmedchem.9b00327 |
| Homo sapiens | LXR-alpha | IC50 | 75.0 | nM | 10.1021/jm800612u |
| Homo sapiens | LXR-alpha | IC50 | 100.0 | nM | 10.1016/j.bmcl.2012.02.028 |
| Homo sapiens | LXR-alpha | IC50 | 14000.0 | nM | 10.1016/j.bmc.2009.04.012 |
| Homo sapiens | LXR-alpha | IC50 | nan | None | 10.1016/j.bmc.2014.03.007 |
| Homo sapiens | LXR-alpha | IC50 | nan | None | 10.1021/acsmedchemlett.5b00170 |
| Homo sapiens | LXR-alpha | IC50 | nan | None | 10.1021/jm3002394 |
| Homo sapiens | LXR-alpha | Kd | 92.4 | nM | 10.1016/j.bmcl.2013.05.030 |
| Homo sapiens | LXR-alpha | Ki | 24.0 | nM | 10.1016/j.bmcl.2016.08.089 |
| Homo sapiens | LXR-alpha | %max | 90.0 | % | 10.1016/j.bmcl.2017.12.006 |
| Homo sapiens | LXR-alpha | max activation | 6.1 | % | 10.1016/j.bmcl.2005.12.015 |
| Homo sapiens | LXR-alpha | Ratio | 1.1 | None | 10.1021/jm901797p |
| Homo sapiens | LXR-alpha | RE | 0.8 | None | 10.1021/jm050532w |
| Homo sapiens | LXR-alpha | RE | 1.0 | None | 10.1021/jm0255116 |
| Homo sapiens | LXR-alpha | RE | 1.1 | None | 10.1021/jm050532w |
| Homo sapiens | LXR-alpha | RE | 2.5 | None | 10.1021/jm0255116 |
| Homo sapiens | LXR-beta | Activity | 45.0 | % | 10.1016/j.bmcl.2013.05.030 |
| Homo sapiens | LXR-beta | Activity | 100.0 | % | 10.1016/j.bmc.2006.12.026 |
| Homo sapiens | LXR-beta | Activity | 100.0 | % | 10.1016/j.bmcl.2007.11.013 |
| Homo sapiens | LXR-beta | Activity | 100.0 | % | 10.1016/j.bmcl.2010.03.031 |
| Homo sapiens | LXR-beta | Activity | nan | None | 10.1016/j.bmcl.2012.04.071 |
| Homo sapiens | LXR-beta | Activity | nan | None | 10.1021/jm100034x |
| Homo sapiens | LXR-beta | Activity | nan | None | 10.1021/jm800612u |
| Homo sapiens | LXR-beta | EC50 | 4.7 | nM | 10.1021/jm101063h |
| Homo sapiens | LXR-beta | EC50 | 8.0 | nM | 10.1016/j.bmcl.2009.02.039 |
| Homo sapiens | LXR-beta | EC50 | 10.0 | nM | 10.1021/acs.jmedchem.6b01126 |
| Homo sapiens | LXR-beta | EC50 | 11.0 | nM | 10.1016/j.bmcl.2007.03.076 |
| Homo sapiens | LXR-beta | EC50 | 11.0 | nM | 10.1016/j.bmcl.2007.06.017 |
| Homo sapiens | LXR-beta | EC50 | 15.0 | nM | 10.1016/j.bmcl.2007.03.076 |
| Homo sapiens | LXR-beta | EC50 | 15.0 | nM | 10.1016/j.bmcl.2007.06.017 |
| Homo sapiens | LXR-beta | EC50 | 16.0 | nM | 10.1016/j.bmc.2009.10.001 |
| Homo sapiens | LXR-beta | EC50 | 16.0 | nM | 10.1021/jm0609566 |
| Homo sapiens | LXR-beta | EC50 | 19.0 | nM | 10.1021/jm100034x |
| Homo sapiens | LXR-beta | EC50 | 20.0 | nM | 10.1021/acs.jmedchem.6b00176 |
| Homo sapiens | LXR-beta | EC50 | 21.0 | nM | 10.1016/j.bmcl.2017.12.024 |
| Homo sapiens | LXR-beta | EC50 | 30.0 | nM | 10.1021/jm050532w |
| Homo sapiens | LXR-beta | EC50 | 50.0 | nM | 10.1021/acs.jmedchem.8b01848 |
| Homo sapiens | LXR-beta | EC50 | 53.0 | nM | 10.1021/jm100034x |
| Homo sapiens | LXR-beta | EC50 | 60.0 | nM | 10.1039/C9MD00264B |
| Homo sapiens | LXR-beta | EC50 | 66.0 | nM | 10.1021/acsmedchemlett.5b00170 |
| Homo sapiens | LXR-beta | EC50 | 75.0 | nM | 10.1016/j.bmcl.2009.02.039 |
| Homo sapiens | LXR-beta | EC50 | 84.0 | % | 10.1016/j.bmcl.2007.06.017 |
| Homo sapiens | LXR-beta | EC50 | 85.0 | nM | 10.1016/j.bmcl.2014.09.053 |
| Homo sapiens | LXR-beta | EC50 | 90.0 | nM | 10.1021/jm3002394 |
| Homo sapiens | LXR-beta | EC50 | 100.0 | nM | 10.1016/j.bmc.2006.12.026 |
| Homo sapiens | LXR-beta | EC50 | 100.0 | nM | 10.1021/jm901797p |
| Homo sapiens | LXR-beta | EC50 | 102.6 | nM | 10.1016/j.bmcl.2013.05.030 |
| Homo sapiens | LXR-beta | EC50 | 110.0 | nM | 10.1016/j.bmcl.2012.04.071 |
| Homo sapiens | LXR-beta | EC50 | 120.0 | nM | 10.1016/j.bmc.2014.03.007 |
| Homo sapiens | LXR-beta | EC50 | 130.0 | nM | 10.1016/j.bmcl.2015.07.047 |
| Homo sapiens | LXR-beta | EC50 | 135.0 | nM | 10.1016/j.bmcl.2009.11.098 |
| Homo sapiens | LXR-beta | EC50 | 140.0 | nM | 10.1016/j.bmcl.2014.11.029 |
| Homo sapiens | LXR-beta | EC50 | 140.0 | nM | 10.1021/jm100034x |
| Homo sapiens | LXR-beta | EC50 | 156.0 | nM | 10.1016/j.bmcl.2013.10.054 |
| Homo sapiens | LXR-beta | EC50 | 160.0 | nM | 10.1021/jm401901d |
| Homo sapiens | LXR-beta | EC50 | 170.0 | nM | 10.1016/j.bmcl.2009.11.062 |
| Homo sapiens | LXR-beta | EC50 | 170.0 | nM | 10.1016/j.bmcl.2010.03.031 |
| Homo sapiens | LXR-beta | EC50 | 170.0 | nM | 10.1021/jm100034x |
| Homo sapiens | LXR-beta | EC50 | 170.0 | nM | 10.1021/jm800799q |
| Homo sapiens | LXR-beta | EC50 | 178.0 | nM | 10.1016/j.bmc.2009.04.012 |
| Homo sapiens | LXR-beta | EC50 | 178.0 | nM | 10.1016/j.bmcl.2007.11.013 |
| Homo sapiens | LXR-beta | EC50 | 198.0 | nM | 10.1016/j.bmcl.2017.12.006 |
| Homo sapiens | LXR-beta | EC50 | 230.0 | nM | 10.1016/j.bmcl.2016.02.031 |
| Homo sapiens | LXR-beta | EC50 | 252.0 | nM | None |
| Homo sapiens | LXR-beta | EC50 | 260.0 | nM | 10.1016/j.bmc.2022.116792 |
| Homo sapiens | LXR-beta | EC50 | 300.0 | nM | 10.1016/j.bmcl.2006.06.081 |
| Homo sapiens | LXR-beta | EC50 | 400.0 | nM | 10.1016/j.bmcl.2015.04.080 |
| Homo sapiens | LXR-beta | EC50 | 410.0 | nM | 10.1016/j.bmc.2016.05.048 |
| Homo sapiens | LXR-beta | EC50 | 410.0 | nM | 10.1016/j.bmcl.2015.01.047 |
| Homo sapiens | LXR-beta | EC50 | 800.0 | nM | 10.1016/j.bmcl.2017.01.066 |
| Homo sapiens | LXR-beta | Efficacy | 100.0 | % | 10.1021/jm800799q |
| Homo sapiens | LXR-beta | Efficacy | 118.0 | % | 10.1021/jm3002394 |
| Homo sapiens | LXR-beta | Efficacy | 140.0 | % | 10.1016/j.bmcl.2014.11.029 |
| Homo sapiens | LXR-beta | Emax | 100.0 | % | 10.1016/j.bmc.2016.05.048 |
| Homo sapiens | LXR-beta | Emax | 100.0 | % | 10.1016/j.bmcl.2015.01.047 |
| Homo sapiens | LXR-beta | Emax | 100.0 | % | 10.1016/j.bmcl.2015.04.080 |
| Homo sapiens | LXR-beta | Emax | 100.0 | % | 10.1021/acs.jmedchem.6b00176 |
| Homo sapiens | LXR-beta | FC | 1.6 | None | 10.1007/s00044-012-0359-5 |
| Homo sapiens | LXR-beta | FC | 284.0 | None | 10.1016/j.bmcl.2013.10.054 |
| Homo sapiens | LXR-beta | IC50 | 9.0 | nM | 10.1016/j.bmc.2009.10.001 |
| Homo sapiens | LXR-beta | IC50 | 9.0 | nM | 10.1016/j.bmcl.2007.11.013 |
| Homo sapiens | LXR-beta | IC50 | 9.0 | nM | 10.1016/j.bmcl.2009.11.062 |
| Homo sapiens | LXR-beta | IC50 | 9.0 | nM | 10.1016/j.bmcl.2010.03.031 |
| Homo sapiens | LXR-beta | IC50 | 9.0 | nM | 10.1021/jm100034x |
| Homo sapiens | LXR-beta | IC50 | 9.0 | nM | 10.1021/jm800799q |
| Homo sapiens | LXR-beta | IC50 | 10.0 | nM | 10.1021/jm0609566 |
| Homo sapiens | LXR-beta | IC50 | 13.0 | nM | 10.1016/j.bmcl.2009.10.132 |
| Homo sapiens | LXR-beta | IC50 | 13.0 | nM | 10.1016/j.bmcl.2009.11.098 |
| Homo sapiens | LXR-beta | IC50 | 13.0 | nM | 10.1016/j.bmcl.2009.11.099 |
| Homo sapiens | LXR-beta | IC50 | 19.95 | nM | 10.1021/jm901797p |
| Homo sapiens | LXR-beta | IC50 | 30.0 | nM | 10.1021/jm800612u |
| Homo sapiens | LXR-beta | IC50 | 70.0 | nM | 10.1016/j.bmcl.2006.06.081 |
| Homo sapiens | LXR-beta | IC50 | 100.0 | nM | 10.1016/j.bmcl.2012.02.028 |
| Homo sapiens | LXR-beta | IC50 | 9000.0 | nM | 10.1016/j.bmc.2009.04.012 |
| Homo sapiens | LXR-beta | IC50 | nan | None | 10.1016/j.bmc.2014.03.007 |
| Homo sapiens | LXR-beta | IC50 | nan | None | 10.1021/acsmedchemlett.5b00170 |
| Homo sapiens | LXR-beta | IC50 | nan | None | 10.1021/jm3002394 |
| Homo sapiens | LXR-beta | Kd | 103.0 | nM | 10.1016/j.bmcl.2013.05.030 |
| Homo sapiens | LXR-beta | Ki | 17.0 | nM | 10.1016/j.bmcl.2016.08.089 |
| Homo sapiens | LXR-beta | Ki | 41.3 | nM | 10.1016/j.ejmech.2019.06.011 |
| Homo sapiens | LXR-beta | Ki | 41.3 | nM | 10.1016/j.ejmech.2020.112240 |
| Homo sapiens | LXR-beta | %max | 100.0 | % | 10.1016/j.bmcl.2017.12.006 |
| Homo sapiens | LXR-beta | Ratio | 1.1 | None | 10.1021/jm901797p |
| Homo sapiens | MAP kinase ERK2 | Delta TM | -0.3422 | C | None |
| Homo sapiens | MAP kinase ERK2 | Delta TM | 0.03 | C | None |
| Homo sapiens | Microtubule-associated protein tau | Potency | 631.0 | nM | None |
| Homo sapiens | Mothers against decapentaplegic homolog 3 | Potency | 22387.2 | nM | None |
| Homo sapiens | Mothers against decapentaplegic homolog 3 | Potency | 35481.3 | nM | None |
| Homo sapiens | Niemann-Pick C1 protein | Activity | nan | None | 10.1016/j.bmcl.2017.04.062 |
| Homo sapiens | Nuclear factor erythroid 2-related factor 2 | Potency | 27306.0 | nM | None |
| Homo sapiens | Nuclear factor erythroid 2-related factor 2 | Potency | 86349.2 | nM | None |
| Homo sapiens | Nuclear factor NF-kappa-B p105 subunit | Potency | 50118.7 | nM | None |
| Homo sapiens | Nuclear receptor ROR-alpha | EC50 | 5000.0 | nM | 10.1016/j.bmcl.2013.10.054 |
| Homo sapiens | Nuclear receptor ROR-alpha | EC50 | 5000.0 | nM | 10.1021/jm401901d |
| Homo sapiens | Nuclear receptor ROR-alpha | IC50 | 2000.0 | nM | 10.1021/acs.jmedchem.8b00588 |
| Homo sapiens | Nuclear receptor ROR-alpha | IC50 | 2000.0 | nM | 10.1021/jm401901d |
| Homo sapiens | Nuclear receptor ROR-alpha | IC50 | 2000.0 | nM | 10.1039/C3MD00005B |
| Homo sapiens | Nuclear receptor ROR-alpha | IC50 | 2000.0 | nM | None |
| Homo sapiens | Nuclear receptor ROR-alpha | IC50 | 2600.0 | nM | 10.1021/acs.jmedchem.9b00327 |
| Homo sapiens | Nuclear receptor ROR-alpha | IC50 | 5011.87 | nM | 10.1016/j.bmcl.2014.09.053 |
| Homo sapiens | Nuclear receptor ROR-alpha | IC50 | 11000.0 | nM | 10.1016/j.bmc.2018.07.038 |
| Homo sapiens | Nuclear receptor ROR-alpha | IC50 | 20000.0 | nM | 10.1016/j.bmc.2014.03.007 |
| Homo sapiens | Nuclear receptor ROR-alpha | IC50 | nan | None | 10.1016/j.bmcl.2016.02.031 |
| Homo sapiens | Nuclear receptor ROR-alpha | Ki | 132.0 | nM | 10.1021/jm401901d |
| Homo sapiens | Nuclear receptor ROR-alpha | Ki | 132.0 | nM | 10.1039/C3MD00005B |
| Homo sapiens | Nuclear receptor ROR-alpha | %max | 55.0 | % | 10.1021/acs.jmedchem.9b00327 |
| Homo sapiens | Nuclear receptor ROR-beta | EC50 | 6000.0 | nM | 10.1016/j.bmcl.2013.10.054 |
| Homo sapiens | Nuclear receptor ROR-beta | EC50 | 6000.0 | nM | 10.1021/jm401901d |
| Homo sapiens | Nuclear receptor ROR-beta | Efficacy | 55.0 | % | 10.1016/j.bmcl.2014.09.053 |
| Homo sapiens | Nuclear receptor ROR-beta | IC50 | 5011.87 | nM | 10.1016/j.bmcl.2014.09.053 |
| Homo sapiens | Nuclear receptor ROR-beta | IC50 | 10000.0 | nM | 10.1016/j.bmcl.2014.09.053 |
| Homo sapiens | Nuclear receptor ROR-beta | IC50 | nan | None | 10.1016/j.bmc.2014.03.007 |
| Homo sapiens | Nuclear receptor ROR-beta | IC50 | nan | None | 10.1016/j.bmcl.2016.02.031 |
| Homo sapiens | Nuclear receptor ROR-beta | IC50 | nan | None | 10.1021/acs.jmedchem.9b00327 |
| Homo sapiens | Nuclear receptor ROR-gamma | EC50 | 54.0 | nM | 10.1016/j.bmcl.2013.10.054 |
| Homo sapiens | Nuclear receptor ROR-gamma | EC50 | 54.0 | nM | 10.1021/jm401901d |
| Homo sapiens | Nuclear receptor ROR-gamma | EC50 | 333.0 | nM | 10.1016/j.bmcl.2017.12.006 |
| Homo sapiens | Nuclear receptor ROR-gamma | EC50 | 460.0 | nM | 10.1021/jm401901d |
| Homo sapiens | Nuclear receptor ROR-gamma | EC50 | 463.0 | nM | 10.1016/j.bmcl.2013.10.054 |
| Homo sapiens | Nuclear receptor ROR-gamma | Efficacy | -99.0 | % | 10.1016/j.bmcl.2013.10.054 |
| Homo sapiens | Nuclear receptor ROR-gamma | Efficacy | 100.0 | % | 10.1016/j.bmcl.2014.09.053 |
| Homo sapiens | Nuclear receptor ROR-gamma | IC50 | 60.0 | nM | 10.1016/j.bmcl.2013.10.054 |
| Homo sapiens | Nuclear receptor ROR-gamma | IC50 | 60.0 | nM | 10.1021/jm401901d |
| Homo sapiens | Nuclear receptor ROR-gamma | IC50 | 204.0 | nM | 10.1016/j.bmcl.2016.03.109 |
| Homo sapiens | Nuclear receptor ROR-gamma | IC50 | 238.0 | nM | 10.1021/acs.jmedchem.1c01746 |
| Homo sapiens | Nuclear receptor ROR-gamma | IC50 | 316.23 | nM | 10.1016/j.bmcl.2014.09.053 |
| Homo sapiens | Nuclear receptor ROR-gamma | IC50 | 330.0 | nM | 10.1021/acs.jmedchem.9b00327 |
| Homo sapiens | Nuclear receptor ROR-gamma | IC50 | 501.19 | nM | 10.1016/j.bmcl.2014.09.053 |
| Homo sapiens | Nuclear receptor ROR-gamma | IC50 | 540.0 | nM | 10.1016/j.ejmech.2014.03.065 |
| Homo sapiens | Nuclear receptor ROR-gamma | IC50 | 810.0 | nM | 10.1021/acs.jmedchem.1c01746 |
| Homo sapiens | Nuclear receptor ROR-gamma | IC50 | 1700.0 | nM | 10.1021/acs.jmedchem.8b00588 |
| Homo sapiens | Nuclear receptor ROR-gamma | IC50 | 1700.0 | nM | 10.1021/jm401901d |
| Homo sapiens | Nuclear receptor ROR-gamma | IC50 | 1700.0 | nM | 10.1039/C3MD00005B |
| Homo sapiens | Nuclear receptor ROR-gamma | IC50 | 1730.0 | nM | None |
| Homo sapiens | Nuclear receptor ROR-gamma | IC50 | 2010.0 | nM | 10.1016/j.ejmech.2014.03.065 |
| Homo sapiens | Nuclear receptor ROR-gamma | IC50 | 3000.0 | nM | 10.1016/j.bmcl.2016.02.031 |
| Homo sapiens | Nuclear receptor ROR-gamma | IC50 | 3500.0 | nM | 10.1016/j.ejmech.2014.03.065 |
| Homo sapiens | Nuclear receptor ROR-gamma | IC50 | 4400.0 | nM | 10.1016/j.bmc.2018.07.038 |
| Homo sapiens | Nuclear receptor ROR-gamma | IC50 | 6500.0 | nM | 10.1016/j.bmc.2014.03.007 |
| Homo sapiens | Nuclear receptor ROR-gamma | Imax | 76.0 | % | 10.1016/j.ejmech.2014.03.065 |
| Homo sapiens | Nuclear receptor ROR-gamma | Imax | 82.0 | % | 10.1016/j.ejmech.2014.03.065 |
| Homo sapiens | Nuclear receptor ROR-gamma | Ki | 51.0 | nM | 10.1021/jm401901d |
| Homo sapiens | Nuclear receptor ROR-gamma | Ki | 51.0 | nM | 10.1039/C3MD00005B |
| Homo sapiens | Parathyroid hormone receptor | Potency | 112201.8 | nM | None |
| Homo sapiens | PBMC | EC50 | 3000.0 | nM | 10.1016/j.bmcl.2013.10.054 |
| Homo sapiens | PBMC | EC50 | 20000.0 | nM | 10.1016/j.bmcl.2013.10.054 |
| Homo sapiens | PBMC | Imax | 81.0 | % | 10.1016/j.bmcl.2013.10.054 |
| Homo sapiens | Peregrin | Delta TM | -0.7765 | C | None |
| Homo sapiens | Peregrin | Delta TM | -0.44 | C | None |
| Homo sapiens | Peroxisome proliferator-activated receptor alpha | Activity | nan | None | 10.1016/j.bmc.2009.04.012 |
| Homo sapiens | Peroxisome proliferator-activated receptor alpha | Activity | nan | None | 10.1016/j.bmcl.2009.11.062 |
| Homo sapiens | Peroxisome proliferator-activated receptor alpha | Activity | nan | None | 10.1021/jm100034x |
| Homo sapiens | Peroxisome proliferator-activated receptor delta | Activity | nan | None | 10.1016/j.bmc.2009.04.012 |
| Homo sapiens | Peroxisome proliferator-activated receptor delta | Activity | nan | None | 10.1016/j.bmcl.2009.11.062 |
| Homo sapiens | Peroxisome proliferator-activated receptor delta | Potency | 44668.4 | nM | None |
| Homo sapiens | Peroxisome proliferator-activated receptor gamma | Activity | nan | None | 10.1016/j.bmc.2009.04.012 |
| Homo sapiens | Peroxisome proliferator-activated receptor gamma | Activity | nan | None | 10.1016/j.bmcl.2009.11.062 |
| Homo sapiens | Peroxisome proliferator-activated receptor gamma | EC50 | nan | None | 10.1016/j.bmcl.2007.11.013 |
| Homo sapiens | Peroxisome proliferator-activated receptor gamma | Potency | 35481.3 | nM | None |
| Homo sapiens | Pregnane X receptor | Activity | 93.0 | % | 10.1016/j.bmc.2006.12.026 |
| Homo sapiens | Pregnane X receptor | Activity | nan | None | 10.1021/acs.jmedchem.0c00012 |
| Homo sapiens | Pregnane X receptor | EC50 | 8.0 | nM | 10.1016/j.bmcl.2017.12.006 |
| Homo sapiens | Pregnane X receptor | EC50 | 12.59 | nM | 10.1016/j.bmc.2006.12.026 |
| Homo sapiens | Pregnane X receptor | EC50 | 15.0 | nM | 10.1021/acs.jmedchem.0c00012 |
| Homo sapiens | Pregnane X receptor | EC50 | 36.0 | nM | 10.1016/j.bmcl.2013.10.054 |
| Homo sapiens | Pregnane X receptor | EC50 | 36.0 | nM | 10.1021/jm401901d |
| Homo sapiens | Pregnane X receptor | EC50 | 50.0 | nM | 10.1021/acsmedchemlett.8b00459 |
| Homo sapiens | Pregnane X receptor | EC50 | 120.0 | nM | 10.1016/j.bmc.2018.07.038 |
| Homo sapiens | Pregnane X receptor | EC50 | 270.0 | nM | 10.1016/j.bmcl.2016.02.031 |
| Homo sapiens | Pregnane X receptor | EC50 | nan | None | 10.1021/acs.jmedchem.0c02201 |
| Homo sapiens | Pregnane X receptor | FC | 22.0 | None | 10.1016/j.bmcl.2013.10.054 |
| Homo sapiens | Pregnane X receptor | IC50 | 26.0 | nM | 10.1021/acs.jmedchem.2c01640 |
| Homo sapiens | Pregnane X receptor | IC50 | 36.0 | nM | 10.1021/acs.jmedchem.0c02201 |
| Homo sapiens | Pregnane X receptor | IC50 | 39.81 | nM | 10.1016/j.bmc.2006.12.026 |
| Homo sapiens | Pregnane X receptor | IC50 | nan | None | 10.1021/acs.jmedchem.0c02201 |
| Homo sapiens | Pregnane X receptor | Inhibition | 100.0 | % | 10.1021/acs.jmedchem.0c02201 |
| Homo sapiens | Pregnane X receptor | Inhibition | 100.0 | % | 10.1021/acs.jmedchem.2c01640 |
| Homo sapiens | Pregnane X receptor | %max | 84.0 | % | 10.1016/j.bmcl.2017.12.006 |
| Homo sapiens | Rap guanine nucleotide exchange factor 3 | Potency | 8912.5 | nM | None |
| Homo sapiens | Rap guanine nucleotide exchange factor 4 | Potency | 44668.4 | nM | None |
| Homo sapiens | Retinoic acid receptor RXR-alpha/oxysterols receptor LXR-alpha | Activity | nan | None | 10.1016/j.bmcl.2015.07.047 |
| Homo sapiens | Retinoic acid receptor RXR-alpha/oxysterols receptor LXR-alpha | EC50 | 0.098 | nM | 10.1016/j.ejmech.2020.112240 |
| Homo sapiens | Retinoic acid receptor RXR-alpha/oxysterols receptor LXR-alpha | Efficacy | 88.0 | % | 10.1016/j.ejmech.2020.112240 |
| Homo sapiens | Retinoic acid receptor RXR-alpha/oxysterols receptor LXR-alpha | Ki | 31.0 | nM | 10.1016/j.bmcl.2014.11.029 |
| Homo sapiens | Retinoic acid receptor RXR-alpha/oxysterols receptor LXR-alpha | Ki | 230.0 | nM | 10.1016/j.bmcl.2015.07.047 |
| Homo sapiens | Retinoic acid receptor RXR-alpha/oxysterols receptor LXR-beta | Activity | nan | None | 10.1016/j.bmcl.2015.07.047 |
| Homo sapiens | Retinoic acid receptor RXR-alpha/oxysterols receptor LXR-beta | EC50 | 0.108 | nM | 10.1016/j.ejmech.2020.112240 |
| Homo sapiens | Retinoic acid receptor RXR-alpha/oxysterols receptor LXR-beta | Efficacy | 100.0 | % | 10.1016/j.ejmech.2020.112240 |
| Homo sapiens | Retinoic acid receptor RXR-alpha/oxysterols receptor LXR-beta | Ki | 26.0 | nM | 10.1016/j.bmcl.2014.11.029 |
| Homo sapiens | Retinoic acid receptor RXR-alpha/oxysterols receptor LXR-beta | Ki | 220.0 | nM | 10.1016/j.bmcl.2015.07.047 |
| Homo sapiens | Retinoid X receptor alpha | Potency | 12589.3 | nM | None |
| Homo sapiens | Serine/threonine-protein kinase Aurora-A | Delta TM | -0.68 | C | None |
| Homo sapiens | Serine/threonine-protein kinase Aurora-A | Delta TM | 0.1476 | C | None |
| Homo sapiens | TAR DNA-binding protein 43 | Potency | 22387.2 | nM | None |
| Homo sapiens | THP-1 | Activity | 0.93 | None | 10.1021/jm7011326 |
| Homo sapiens | THP-1 | Activity | 1.0 | None | 10.1021/jm800612u |
| Homo sapiens | THP-1 | Activity | 1.05 | None | 10.1021/jm7011326 |
| Homo sapiens | THP-1 | Activity | 1.17 | None | 10.1021/jm7011326 |
| Homo sapiens | THP-1 | Activity | 1.26 | None | 10.1021/jm7011326 |
| Homo sapiens | THP-1 | Activity | 1.78 | None | 10.1021/jm7011326 |
| Homo sapiens | THP-1 | Activity | 2.59 | None | 10.1021/jm7011326 |
| Homo sapiens | THP-1 | Activity | 4.09 | None | 10.1021/jm7011326 |
| Homo sapiens | THP-1 | Activity | 4.2 | None | 10.1021/jm7011326 |
| Homo sapiens | THP-1 | Activity | 4.56 | None | 10.1021/jm7011326 |
| Homo sapiens | THP-1 | Activity | 5.9 | None | 10.1021/jm7011326 |
| Homo sapiens | THP-1 | Activity | 8.16 | None | 10.1021/jm7011326 |
| Homo sapiens | THP-1 | Activity | 15.05 | None | 10.1021/jm7011326 |
| Homo sapiens | THP-1 | Activity | 100.0 | % | 10.1016/j.bmcl.2007.11.013 |
| Homo sapiens | THP-1 | Activity | nan | None | 10.1021/acsmedchemlett.5b00170 |
| Homo sapiens | THP-1 | Activity | nan | None | 10.1021/jm901797p |
| Homo sapiens | THP-1 | EC50 | 3.0 | nM | 10.1016/j.bmcl.2009.11.062 |
| Homo sapiens | THP-1 | EC50 | 3.0 | nM | 10.1021/jm800799q |
| Homo sapiens | THP-1 | EC50 | 33.0 | nM | 10.1016/j.bmcl.2007.03.076 |
| Homo sapiens | THP-1 | EC50 | 33.0 | nM | 10.1016/j.bmcl.2007.06.017 |
| Homo sapiens | THP-1 | EC50 | 35.0 | nM | 10.1016/j.bmcl.2009.11.099 |
| Homo sapiens | THP-1 | EC50 | 44.0 | nM | 10.1016/j.bmcl.2007.11.013 |
| Homo sapiens | THP-1 | EC50 | 44.0 | nM | 10.1016/j.bmcl.2009.11.062 |
| Homo sapiens | THP-1 | EC50 | 44.0 | nM | 10.1016/j.bmcl.2009.11.098 |
| Homo sapiens | THP-1 | EC50 | 44.0 | nM | 10.1021/jm100034x |
| Homo sapiens | THP-1 | EC50 | 44.0 | nM | 10.1021/jm800799q |
| Homo sapiens | THP-1 | Efficacy | 100.0 | % | 10.1016/j.bmcl.2009.11.098 |
| Homo sapiens | THP-1 | Efficacy | 100.0 | % | 10.1016/j.bmcl.2009.11.099 |
| Homo sapiens | THP-1 | Efficacy | 100.0 | % | 10.1021/jm800799q |
| Homo sapiens | THP-1 | IC50 | 100.0 | nM | 10.1021/jm800612u |
| Homo sapiens | THP-1 | Ratio | 1.6 | None | 10.1016/j.bmcl.2007.03.076 |
| Homo sapiens | THP-1 | Ratio | 1.6 | None | 10.1016/j.bmcl.2007.06.017 |
| Homo sapiens | THP-1 | Ratio | 6.7 | None | 10.1016/j.bmcl.2007.03.076 |
| Homo sapiens | THP-1 | Ratio | 8.4 | None | 10.1016/j.bmcl.2007.03.076 |
| Homo sapiens | THP-1 | Ratio | 8.4 | None | 10.1016/j.bmcl.2007.06.017 |
| Homo sapiens | Thyroid hormone receptor beta-1 | Potency | 44.7 | nM | None |
| Homo sapiens | Transcription intermediary factor 1-alpha | Delta TM | -1.201 | C | None |
| Homo sapiens | Transcription intermediary factor 1-alpha | Delta TM | 0.39 | C | None |
| Homo sapiens | Tyrosine-protein kinase ABL | Delta TM | -0.7513 | C | None |
| Homo sapiens | Tyrosine-protein kinase ABL | Delta TM | 0.78 | C | None |
| Homo sapiens | Tyrosyl-DNA phosphodiesterase 1 | Potency | 20596.2 | nM | None |
| Homo sapiens | Tyrosyl-DNA phosphodiesterase 1 | Potency | 22387.2 | nM | None |
| Homo sapiens | Tyrosyl-DNA phosphodiesterase 1 | Potency | 29092.9 | nM | None |
| Homo sapiens | Tyrosyl-DNA phosphodiesterase 1 | Potency | 35481.3 | nM | None |
| Homo sapiens | U2OS | Control DMSO Fragmented Nuclei % | 3.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Control DMSO Fragmented Nuclei % | 4.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Control DMSO Fragmented Nuclei % | 6.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Control DMSO Fragmented Nuclei % | 11.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Control DMSO Fragmented Nuclei % | 13.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Control DMSO Fragmented Nuclei % | 17.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Control DMSO Fragmented Nuclei % | 39.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Control DMSO Healthy Nuclei (%) | 54.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Control DMSO Healthy Nuclei (%) | 70.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Control DMSO Healthy Nuclei (%) | 73.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Control DMSO Healthy Nuclei (%) | 77.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Control DMSO Healthy Nuclei (%) | 81.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Control DMSO Healthy Nuclei (%) | 87.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Control DMSO Healthy Nuclei (%) | 89.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Control DMSO Healthy Nuclei (%) | 90.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Control DMSO Membrane Permeable-Phenotype Cells (%) | 1.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Control DMSO Membrane Permeable-Phenotype Cells (%) | 2.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Control DMSO Membrane Permeable-Phenotype Cells (%) | 3.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Control DMSO Membrane Permeable-Phenotype Cells (%) | 9.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Control DMSO Mitochondria Different-Phenotype Cells (%) | 0.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Control DMSO Mitochondria Different-Phenotype Cells (%) | 1.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Control DMSO Mitotic Cells (%) | 32.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Control DMSO Mitotic Cells (%) | 39.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Control DMSO Mitotic Cells (%) | 42.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Control DMSO Mitotic Cells (%) | 48.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Control DMSO Mitotic Cells (%) | 50.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Control DMSO Mitotic Cells (%) | 52.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Control DMSO Mitotic Cells (%) | 60.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Control DMSO Mitotic Cells (%) | 62.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Control DMSO Pyknosed Nuclei (%) | 6.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Control DMSO Pyknosed Nuclei (%) | 7.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Control DMSO Pyknosed Nuclei (%) | 8.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Control DMSO Pyknosed Nuclei (%) | 10.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Control DMSO Pyknosed Nuclei (%) | 11.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Control DMSO Pyknosed Nuclei (%) | 12.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Control DMSO Pyknosed Nuclei (%) | 13.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Control DMSO Total Cells | 33.0 | None | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Control DMSO Total Cells | 43.0 | None | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Control DMSO Total Cells | 54.0 | None | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Control DMSO Total Cells | 92.0 | None | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Control DMSO Total Cells | 149.0 | None | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Control DMSO Total Cells | 255.0 | None | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Control DMSO Total Cells | 361.0 | None | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Control DMSO Total Cells | 732.0 | None | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Control DMSO Tubulin Phenotype Different Cells (%) | 1.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Control DMSO Tubulin Phenotype Different Cells (%) | 7.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Control DMSO Tubulin Phenotype Different Cells (%) | 64.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Control DMSO Tubulin Phenotype Different Cells (%) | 69.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Control DMSO Tubulin Phenotype Different Cells (%) | 70.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Control DMSO Tubulin Phenotype Different Cells (%) | 91.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Control DMSO Tubulin Phenotype Different Cells (%) | 92.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Control DMSO Tubulin Phenotype Different Cells (%) | 93.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Growth Rate | -0.29 | None | 10.6019/CHEMBL5058564 |
| Homo sapiens | U2OS | Growth Rate | 0.0 | None | 10.6019/CHEMBL4689842 |
| Homo sapiens | U2OS | Growth Rate | 0.14 | None | 10.6019/CHEMBL5058564 |
| Homo sapiens | U2OS | Growth Rate | 0.74 | None | 10.6019/CHEMBL5058564 |
| Homo sapiens | U2OS | Growth Rate | 0.76 | None | 10.6019/CHEMBL5058564 |
| Homo sapiens | U2OS | Growth Rate | 0.81 | None | 10.6019/CHEMBL5058564 |
| Homo sapiens | U2OS | Growth Rate | 0.83 | None | 10.6019/CHEMBL5058564 |
| Homo sapiens | U2OS | Growth Rate | 0.98 | None | 10.6019/CHEMBL5058564 |
| Homo sapiens | U2OS | Growth Rate | 1.0 | None | 10.6019/CHEMBL4689842 |
| Homo sapiens | U2OS | Population Apoptotic (%) | 0.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Population Apoptotic (%) | 33.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Population Apoptotic (%) | 35.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Population Apoptotic (%) | 36.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Population Apoptotic (%) | 39.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Population Apoptotic (%) | 45.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Population Apoptotic (%) | 50.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Population Apoptotic (%) | 52.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Population Apoptotic (%) | 56.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Population Apoptotic (%) | 57.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Population Apoptotic (%) | 66.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Population Apoptotic (%) | 75.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Population Apoptotic (%) | 79.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Population Apoptotic (%) | 100.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Population Fragmented Nuclei (%) | 2.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Population Fragmented Nuclei (%) | 3.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Population Fragmented Nuclei (%) | 4.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Population Fragmented Nuclei (%) | 5.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Population Fragmented Nuclei (%) | 6.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Population Fragmented Nuclei (%) | 7.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Population Fragmented Nuclei (%) | 15.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Population Fragmented Nuclei (%) | 20.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Population Fragmented Nuclei (%) | 24.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Population Fragmented Nuclei (%) | 27.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Population Fragmented Nuclei (%) | 35.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Population Fragmented Nuclei (%) | 36.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Population Fragmented Nuclei (%) | 40.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Population Fragmented Nuclei (%) | 64.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Population Healthy Nuclei (%) | 35.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Population Healthy Nuclei (%) | 56.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Population Healthy Nuclei (%) | 58.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Population Healthy Nuclei (%) | 62.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Population Healthy Nuclei (%) | 65.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Population Healthy Nuclei (%) | 70.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Population Healthy Nuclei (%) | 78.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Population Healthy Nuclei (%) | 80.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Population Healthy Nuclei (%) | 81.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Population Healthy Nuclei (%) | 82.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Population Healthy Nuclei (%) | 86.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Population Healthy Nuclei (%) | 88.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Population Healthy Nuclei (%) | 90.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Population Hoechst High Intensity Objects (%) | 0.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Population Hoechst High Intensity Objects (%) | 2.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Population Hoechst High Intensity Objects (%) | 3.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Population Membrane Permeable-Phenotype (%) | 0.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Population Membrane Permeable-Phenotype (%) | 1.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Population Membrane Permeable-Phenotype (%) | 2.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Population Membrane Permeable-Phenotype (%) | 3.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Population Membrane Permeable-Phenotype (%) | 4.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Population Membrane Permeable-Phenotype (%) | 5.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Population Membrane Permeable-Phenotype (%) | 10.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Population Membrane Permeable-Phenotype (%) | 13.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Population Membrane Permeable-Phenotype (%) | 16.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Population Membrane Permeable-Phenotype (%) | 19.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Population Mitochondria Different-Phenotype (%) | 0.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Population Mitochondria Different-Phenotype (%) | 1.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Population Mitochondria Different-Phenotype (%) | 2.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Population Mitochondria Different-Phenotype (%) | 3.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Population Mitochondria Different-Phenotype (%) | 5.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Population Mitochondria Different-Phenotype (%) | 8.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Population Mitochondria Different-Phenotype (%) | 10.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Population Mitotic Cells (%) | 0.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Population Mitotic Cells (%) | 20.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Population Mitotic Cells (%) | 25.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Population Mitotic Cells (%) | 33.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Population Mitotic Cells (%) | 42.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Population Mitotic Cells (%) | 43.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Population Mitotic Cells (%) | 47.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Population Mitotic Cells (%) | 50.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Population Mitotic Cells (%) | 54.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Population Mitotic Cells (%) | 60.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Population Mitotic Cells (%) | 63.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Population Mitotic Cells (%) | 64.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Population Mitotic Cells (%) | 66.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Population Normal (%) | 96.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Population Normal (%) | 97.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Population Normal (%) | 100.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Population Pyknosed Nuclei (%) | 0.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Population Pyknosed Nuclei (%) | 2.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Population Pyknosed Nuclei (%) | 4.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Population Pyknosed Nuclei (%) | 6.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Population Pyknosed Nuclei (%) | 7.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Population Pyknosed Nuclei (%) | 9.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Population Pyknosed Nuclei (%) | 10.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Population Pyknosed Nuclei (%) | 11.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Population Pyknosed Nuclei (%) | 12.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Population Pyknosed Nuclei (%) | 13.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Population Pyknosed Nuclei (%) | 14.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Population Pyknosed Nuclei (%) | 16.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Population Tubulin-Different-Phenotype (%) | 0.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Population Tubulin-Different-Phenotype (%) | 34.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Population Tubulin-Different-Phenotype (%) | 40.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Population Tubulin-Different-Phenotype (%) | 41.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Population Tubulin-Different-Phenotype (%) | 47.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Population Tubulin-Different-Phenotype (%) | 52.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Population Tubulin-Different-Phenotype (%) | 58.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Population Tubulin-Different-Phenotype (%) | 59.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Population Tubulin-Different-Phenotype (%) | 72.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Population Tubulin-Different-Phenotype (%) | 81.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Population Tubulin-Different-Phenotype (%) | 82.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Population Tubulin-Different-Phenotype (%) | 84.0 | % | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Total Cell Count | 37.0 | None | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Total Cell Count | 38.0 | None | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Total Cell Count | 39.0 | None | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Total Cell Count | 41.0 | None | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Total Cell Count | 49.0 | None | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Total Cell Count | 63.0 | None | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Total Cell Count | 65.0 | None | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Total Cell Count | 121.0 | None | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Total Cell Count | 165.0 | None | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Total Cell Count | 183.0 | None | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Total Cell Count | 217.0 | None | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Total Cell Count | 224.0 | None | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Total Cell Count | 317.0 | None | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Total Cell Count | 326.0 | None | 10.6019/CHEMBL5303300 |
| Homo sapiens | U2OS | Total Cell Count | 643.0 | None | 10.6019/CHEMBL5303300 |
| Homo sapiens | U-87 MG | IC50 | nan | None | 10.1016/j.ejmech.2020.112240 |
| Homo sapiens | Vitamin D receptor | Potency | 35481.3 | nM | None |
| Homo sapiens | Vitamin D receptor | Potency | 50118.7 | nM | None |
| Macaca fascicularis | Cynomolgus monkey | FC | 6.0 | None | 10.1021/acsmedchemlett.6b00234 |
| Macaca mulatta | Rhesus monkey | Activity | 25.0 | % | 10.1021/acs.jmedchem.6b00176 |
| Macaca mulatta | Rhesus monkey | Activity | nan | None | 10.1021/acs.jmedchem.6b00176 |
| Macaca mulatta | Rhesus monkey | FC | 4.0 | None | 10.1021/acs.jmedchem.6b00176 |
| Mus musculus | J774 | Activity | 100.0 | % | 10.1016/j.bmcl.2007.11.013 |
| Mus musculus | J774 | Activity | 100.0 | % | 10.1016/j.bmcl.2010.03.031 |
| Mus musculus | J774 | EC50 | 35.0 | nM | 10.1016/j.bmcl.2007.11.013 |
| Mus musculus | J774 | EC50 | 35.0 | nM | 10.1016/j.bmcl.2010.03.031 |
| Mus musculus | J774.A1 | EC50 | 34.0 | nM | 10.1016/j.bmc.2009.04.012 |
| Mus musculus | J774.A1 | EC50 | 35.0 | nM | 10.1016/j.bmcl.2009.10.132 |
| Mus musculus | J774.A1 | Efficacy | 100.0 | % | 10.1016/j.bmcl.2009.10.132 |
| Mus musculus | Liver | Drug uptake | 7900.0 | ng/g | 10.1016/j.bmcl.2009.01.109 |
| Mus musculus | Mus musculus | Activity | 20.0 | % | 10.1016/j.bmcl.2009.01.109 |
| Mus musculus | Mus musculus | Activity | 23.0 | % | 10.1016/j.bmcl.2009.01.109 |
| Mus musculus | Mus musculus | Activity | 40.0 | % | 10.1016/j.bmc.2016.05.048 |
| Mus musculus | Mus musculus | Activity | 47.0 | % | 10.1016/j.bmc.2016.05.048 |
| Mus musculus | Mus musculus | Activity | 55.0 | % | 10.1016/j.bmc.2016.05.048 |
| Mus musculus | Mus musculus | Activity | 96.0 | % | 10.1016/j.bmc.2016.05.048 |
| Mus musculus | Mus musculus | Activity | 270.0 | % | 10.1016/j.bmcl.2009.01.109 |
| Mus musculus | Mus musculus | Activity | 465.0 | % | 10.1016/j.bmc.2016.05.048 |
| Mus musculus | Mus musculus | Activity | nan | None | 10.1016/j.bmcl.2015.07.047 |
| Mus musculus | Mus musculus | Activity | nan | None | 10.1016/j.ejmech.2019.111647 |
| Mus musculus | Mus musculus | Activity | nan | None | 10.1021/acs.jmedchem.6b00176 |
| Mus musculus | Mus musculus | Activity | nan | None | 10.1021/jm100034x |
| Mus musculus | Mus musculus | AUC | 3421.0 | ng.hr.mL-1 | 10.1016/j.bmcl.2005.12.015 |
| Mus musculus | Mus musculus | Cp | 255.0 | ng/ml | 10.1016/j.bmcl.2009.01.109 |
| Mus musculus | Mus musculus | FC | 1.0 | None | 10.1016/j.bmcl.2009.02.039 |
| Mus musculus | Mus musculus | FC | 1.5 | None | 10.1016/j.bmcl.2009.02.039 |
| Mus musculus | Mus musculus | FC | 2.5 | None | 10.1016/j.bmc.2016.05.048 |
| Mus musculus | Mus musculus | FC | 2.9 | None | 10.1016/j.bmc.2016.05.048 |
| Mus musculus | Mus musculus | FC | 4.5 | None | 10.1016/j.bmcl.2016.08.089 |
| Mus musculus | Mus musculus | T1/2 | 3.0 | hr | 10.1016/j.bmcl.2005.12.015 |
| Mus musculus | Nuclear receptor ROR-alpha | IC20 | 12.0 | uM | 10.1039/C3MD00005B |
| Mus musculus | Nuclear receptor ROR-gamma | IC20 | 1.0 | uM | 10.1039/C3MD00005B |
| Mus musculus | Nuclear receptor ROR-gamma | Potency | 1995.3 | nM | None |
| Mus musculus | Oxysterols receptor LXR-beta | EC50 | 27.0 | nM | 10.1016/j.bmc.2009.10.001 |
| Mus musculus | Retinoid X receptor alpha | Activity | nan | None | 10.1021/acs.jmedchem.0c01354 |
| Rattus norvegicus | Liver microsomes | T1/2 | 0.5 | hr | 10.1016/j.bmcl.2009.10.132 |
| Rattus norvegicus | Liver microsomes | T1/2 | 0.5 | hr | 10.1016/j.bmcl.2009.11.098 |
| Rattus norvegicus | Liver microsomes | T1/2 | 0.5 | hr | 10.1016/j.bmcl.2010.03.031 |
| Rattus norvegicus | Nuclear receptor subfamily 1 group I member 2 | Potency | 1122.0 | nM | None |
| Rattus norvegicus | Oxysterols receptor LXR-beta | EC50 | 30.0 | nM | 10.1016/j.bmcl.2019.03.051 |
| Rattus norvegicus | Oxysterols receptor LXR-beta | Efficacy | 98.0 | % | 10.1016/j.bmcl.2019.03.051 |
| Rattus norvegicus | Rattus norvegicus | Activity | nan | None | 10.1016/j.bmcl.2016.08.089 |
| Rattus norvegicus | Rattus norvegicus | AUC | 5920.0 | ng.hr.mL-1 | 10.1016/j.bmcl.2005.12.015 |
| Rattus norvegicus | Rattus norvegicus | FC | 5.0 | None | 10.1016/j.bmcl.2016.08.089 |
| Severe acute respiratory syndrome coronavirus 2 | Replicase polyprotein 1ab | Inhibition | -3.18 | % | 10.6019/CHEMBL4495564 |
| Severe acute respiratory syndrome coronavirus 2 | Replicase polyprotein 1ab | Inhibition | 14.15 | % | 10.6019/CHEMBL4495564 |
| Severe acute respiratory syndrome coronavirus 2 | SARS-CoV-2 | Inhibition | -2.79 | % | 10.21203/rs.3.rs-23951/v1 |
| Severe acute respiratory syndrome coronavirus 2 | SARS-CoV-2 | Inhibition | -0.04 | % | 10.6019/CHEMBL4495565 |
| Severe acute respiratory syndrome coronavirus 2 | SARS-CoV-2 | Inhibition | 2.69 | % | 10.6019/CHEMBL4495565 |
| None | ADMET | Activity | nan | None | 10.1016/j.bmc.2022.116792 |
| None | ADMET | Activity | nan | None | 10.1016/j.ejmech.2019.111647 |
| None | ADMET | Activity | nan | None | 10.1021/jm3002394 |
| None | ADMET | CL | 3.0 | mL.min-1.g-1 | 10.6019/CHEMBL3301361 |
| None | ADMET | CL | 5.37 | uL.min-1.(10^6cells)-1 | 10.6019/CHEMBL3301361 |
| None | ADMET | CL | 14.13 | uL.min-1.(10^6cells)-1 | 10.6019/CHEMBL3301361 |
| None | ADMET | CLH | nan | None | 10.1021/acs.jmedchem.1c01746 |
| None | ADMET | Cp | 200.0 | nM | 10.1021/acsmedchemlett.6b00234 |
| None | ADMET | Cp | 2796.0 | nM | 10.1016/j.bmcl.2016.08.089 |
| None | ADMET | Cp | 3768.0 | nM | 10.1016/j.bmcl.2016.08.089 |
| None | ADMET | Drug uptake | 5364.0 | nM | 10.1016/j.bmcl.2016.08.089 |
| None | ADMET | Drug uptake | 8048.0 | nM | 10.1016/j.bmcl.2016.08.089 |
| None | ADMET | PPB | 99.56 | % | 10.6019/CHEMBL3301361 |
| None | ADMET | PPB | 99.71 | % | 10.6019/CHEMBL3301361 |
| None | ADMET | Stability | 65.0 | % | 10.1021/jm800612u |
| None | ADMET | t1/2 | nan | None | 10.1021/acs.jmedchem.1c01746 |
| None | ADMET | T1/2 | 0.5 | hr | 10.1016/j.bmcl.2009.11.098 |
| None | ADMET | TI | 10.0 | None | 10.1016/j.ejmech.2016.07.005 |
| None | Molecular identity unknown | Inhibition | nan | % | 10.1021/jm3002394 |
| None | Molecular identity unknown | Potency | 20.0 | nM | None |
| None | NON-PROTEIN TARGET | Activity | 73.3 | % | 10.1016/j.ejmech.2016.07.005 |
| None | NON-PROTEIN TARGET | Activity | 94.8 | % | 10.1016/j.ejmech.2016.07.005 |
| None | NON-PROTEIN TARGET | Activity | 140.0 | % | 10.1021/acsmedchemlett.6b00234 |
| None | NON-PROTEIN TARGET | IC50 | 50000.0 | nM | 10.1016/j.ejmech.2016.07.005 |
| None | No relevant target | LogD7.4 | 4.5 | None | 10.6019/CHEMBL3301361 |
| None | No relevant target | LogP | 5.38 | None | 10.1016/j.bmc.2018.07.038 |
| None | No relevant target | LogP | 5.38 | None | 10.1016/j.bmcl.2016.02.031 |
| None | Peritoneal macrophage cell | Inhibition | nan | % | 10.1021/jm3002394 |
| None | Unchecked | AbsAC40_uM | 6.8 | uM | None |
| None | Unchecked | Activity | 64.2 | % | 10.1016/j.ejmech.2016.07.005 |
| None | Unchecked | Activity | 380.0 | % | 10.1021/acsmedchemlett.9b00306 |
| None | Unchecked | Activity | nan | None | 10.1016/j.bmc.2008.02.078 |
| None | Unchecked | Activity | nan | None | 10.1016/j.bmc.2013.10.024 |
| None | Unchecked | Activity | nan | None | 10.1016/j.ejmech.2016.07.005 |
| None | Unchecked | Activity | nan | None | 10.1021/acs.jmedchem.7b00091 |
| None | Unchecked | EC50 | 70.0 | nM | 10.1021/jm050532w |
| None | Unchecked | EC50 | 201.0 | nM | 10.1021/acs.jmedchem.0c01065 |
| None | Unchecked | EC50 | 310.0 | nM | 10.1021/acsmedchemlett.6b00234 |
| None | Unchecked | Efficacy | 100.0 | % | 10.1021/acsmedchemlett.6b00234 |
| None | Unchecked | IC50 | 50.0 | nM | 10.1021/acs.jmedchem.0c00262 |
| None | Unchecked | IC50 | 100000.0 | nM | 10.1016/j.bmc.2008.02.078 |
| None | Unchecked | Inhibition | 52.7 | % | 10.1016/j.bmc.2022.116936 |
| None | Unchecked | Potency | 2238.7 | nM | None |
| None | Unchecked | Potency | 8912.5 | nM | None |
| None | Unchecked | Potency | 11220.2 | nM | None |
| None | Unchecked | Potency | 18356.4 | nM | None |
| None | Unchecked | Potency | 22387.2 | nM | None |
| None | Unchecked | Potency | 39810.7 | nM | None |
| None | Unchecked | Potency | 50118.7 | nM | None |
| None | Unchecked | Ratio EC50 | 0.9 | None | 10.1016/j.ejmech.2020.112240 |
| None | Unchecked | Ratio EC50 | 1.01 | None | 10.1016/j.bmc.2022.116792 |
| None | Unchecked | Ratio EC50 | 10.0 | None | 10.1016/j.bmcl.2013.10.054 |
| None | Unchecked | RE | 1.0 | None | 10.1021/jm050532w |
